Diabetics using TZDs face higher bladder cancer risk
This article was originally published in Scrip
Patients taking thiazolidinedione (TZD) drugs – which account for up to 20% of drugs prescribed to diabetics in the US – are two to three times more likely to develop bladder cancer than those taking a sulfonylurea drug, according to a new study published online in the Journal of the National Cancer Institute by researchers from the Perelmen School of Medicine at the University of Pennsylvania.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.